Hsiaowei Deng

Johnson & Johnson (United States) — United States

Medicine · Health Sciences

8h-index1.4kcitations23works6.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(10), Pancreatic function and diabetes(5), Atrial Fibrillation Management and Outcomes(4), Antiplatelet Therapy and Cardiovascular Diseases(4), Diabetes Management and Research(3)

Publications23 total

Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD
Journal of the American Heart Association·2025· 1 citedOpen Access
Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)
American Heart Journal·2025· 10 citedOpen Access
Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial
Journal of the American Heart Association·2024· 7 citedOpen Access
Review for "Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus <scp>dipeptidyl peptidase‐4</scp> inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data"
2023
Evaluation of the benefit of rivaroxaban on VOYAGER PAD primary composite of limb, heart and brain outcomes using the global rank and win ratio methods
European Heart Journal·2022· 1 citedOpen Access
Review for "Association between antidiabetic drug use and the risk of COVID-19 hospitalization in the INSIGHT Clinical Research Network in New York City"
2021
Review for "Association of obesity with postacute sequelae of COVID-19"
2021
Review for "High-Dose Sodium-Glucose Co-transporter 2 Inhibitors are Superior in Type 2 Diabetes: A Meta-analysis of Randomised Clinical Trials"
2021
Efficacy of rivaroxaban compared to standard of care in preventing ischemic stroke in adults with coronary or peripheral vascular disease: an integrated analysis using patient-level data
European Heart Journal·2020
Review for "Prevalence of comorbidities and their association with mortality in patients with <scp>COVID</scp> ‐19: A Systematic Review and Meta‐analysis"
2020Open Access
Review for "Prevalence of comorbidities and their association with mortality in patients with <scp>COVID</scp> ‐19: A Systematic Review and Meta‐analysis"
2020
Review for "<scp>SGLT2</scp> inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta‐analysis of randomized controlled trials"
2020
Review for "Evaluation of the safety of <scp>SGLT</scp> ‐2 inhibitors for treating patients with type 1 diabetes"
2020
Review for "<scp>SGLT2</scp> inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta‐analysis of randomized controlled trials"
2020· 2 cited
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial
JACC Heart Failure·2020· 19 citedOpen Access
A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial
European Heart Journal·2019· 95 citedOpen Access
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm
JAMA Cardiology·2019· 66 citedOpen Access
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function
Circulation·2018· 245 citedOpen Access
Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease
Diabetes·2018
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
The Lancet Diabetes & Endocrinology·2018· 633 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Kenneth W. Mahaffey(6), Vlado Perkovic(5), Greg Fulcher(5), David R. Matthews(5), Bruce Neal(5), Dick de Zeeuw(4), Mehul Desai(4), Ngozi Erondu(3), Wayne Shaw(3), Mandeep R. Mehra(3), John G.F. Cleland(3), Carolyn S.P. Lam(3), Dirk J. van Veldhuisen(3), William M. Byra(3), Theodore E. Spiro(3), Faı̈ez Zannad(3), Barry Greenberg(3), Michael Szarek(3), Rupert Bauersachs(3), Scott D. Berkowitz(3)